Načítá se...

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance

The Human Epidermal Growth Factor Receptor 2 (Her2, ErbB2 or Neu) is overexpressed in about 20 – 25% of breast cancers and is causally linked to oncogenesis, providing opportunities for targeted therapy. Trastuzumab (Herceptin(™), Genentech Inc, San Francisco, CA), a humanized monoclonal antibody ag...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bailey, Tameka A., Luan, Haitao, Clubb, Robert J., Naramura, Mayumi, Band, Vimla, Raja, Srikumar M., Band, Hamid
Médium: Artigo
Jazyk:Inglês
Vydáno: Medknow Publications & Media Pvt Ltd 2011
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3243087/
https://ncbi.nlm.nih.gov/pubmed/22190870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1477-3163.90442
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!